Company OpGen, Inc.

Equities

OPGN

US68373L5057

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-21 pm EDT			5-day change	1st Jan Change
3.48 ^USD	-9.85%		-21.27%	-17.15%

Apr. 24	OpGen Gets Notice of Noncompliance From Nasdaq	MT
Mar. 26	Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	MT

OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Companyâs product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Companyâs subsidiaries include Curetis GmbH and Ares Genetics GmbH.

Number of employees: 93

USD in Million	2021	Weight	2022	Weight	Delta
Molecular Diagnostics and Informatics 72.6 %	3	61.7 %	2	72.6 %	-28.71%
Collaboration 20.7 %	1	19.4 %	1	20.7 %	-35.32%
Laboratory Services 6.6 %	1	18.9 %	0	6.6 %	-78.77%

USD in Million	2021	Weight	2022	Weight	Delta
International 80.0 %	3	72.0 %	2	80.0 %	-32.74%
United States 20.0 %	1	28.0 %	1	20.0 %	-56.75%

Managers	Title	Age	Since
Albert Weber DFI	Director of Finance/CFO	60	21-12-31
Johannes Bacher COO	Chief Operating Officer	55	20-03-31
Oliver Schacht PRN	Corporate Officer/Principal	53	20-03-31

Members of the board	Title	Age	Since
Oliver Schacht PRN	Corporate Officer/Principal	53	20-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,262,490	119,747 ( 9.485 %)	0	9.485 %

Name	Equities	%	Valuation
Chase Investment Counsel Corp. 2.629 %	331,890	2.629 %	176 565 $
David Natan 0.7921 %	100,000	0.7921 %	53 200 $
Avraham Ben-Tzvi 0.7921 %	100,000	0.7921 %	53 200 $
David Lazar 0.7921 %	100,000	0.7921 %	53 200 $
Matthew McMurdo 0.7921 %	100,000	0.7921 %	53 200 $
Vanguard Group, Inc. (Subfiler) 0.4220 %	53,275	0.4220 %	28 342 $
Geode Capital Management LLC 0.2875 %	36,301	0.2875 %	19 312 $
SVB Wealth LLC 0.1443 %	18,219	0.1443 %	9 693 $
BlackRock Institutional Trust Co. NA 0.1263 %	15,941	0.1263 %	8 481 $
Tower Research Capital LLC 0.0589 %	7,436	0.0589 %	3 956 $

OpGen, Inc.

9717 Key West Avenue Suite 100

20850, Rockville

+240 813 1260

http://www.opgen.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
OPGEN, INC.	-17.15%	4.39M
MODERNA, INC.	+44.48%	55.07B
LONZA GROUP AG	+43.06%	40.22B
IQVIA HOLDINGS INC.	-0.86%	41.79B
CELLTRION, INC.	-7.59%	28.17B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.28B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	18.93B
BIO-TECHNE CORPORATION	+7.15%	13.03B
MEDPACE HOLDINGS, INC.	+29.40%	12.26B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.21B

Other Biotechnology & Medical Research